Parlux second-quarter net earnings double to $1.5 mil. on an 83% sales increase.
This article was originally published in The Rose Sheet
Executive Summary
PERRY ELLIS LINE REPRESENTS MORE THAN 40% OF PARLUX' SECOND-QUARTER SALES of $13.9 mil. Acquired from Sanofi at the end of 1994 ("The Rose Sheet" Jan. 2, In Brief), the Perry Ellis line generated sales of $5.6 mil. in the second quarter (ended Sept. 30). Compared to the same three-month period in the previous fiscal year, Parlux sales increased 83%. Excluding revenues from Perry Ellis, sales rose nearly 10%